CIPLA
|
CIPLA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 48.02 | 65.29 | 51.05 | 34.71 | 31.19 |
| CEPS(Rs) | 62.90 | 79.22 | 64.49 | 49.65 | 44.76 |
| DPS(Rs) | 13.00 | 16.00 | 13.00 | 8.50 | 5.00 |
| Book NAV/Share(Rs) | 425.47 | 384.84 | 329.72 | 289.24 | 257.78 |
| Tax Rate(%) | 25.92 | 22.43 | 27.12 | 29.79 | 26.73 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 15.08 | 19.23 | 17.76 | 16.13 | 15.18 |
| EBIT Margin(%) | 13.53 | 18.58 | 16.35 | 13.41 | 12.11 |
| Pre Tax Margin(%) | 13.39 | 18.42 | 16.10 | 13.05 | 11.75 |
| PAT Margin (%) | 9.92 | 14.29 | 11.73 | 9.17 | 8.61 |
| Cash Profit Margin (%) | 13.02 | 17.27 | 14.70 | 12.95 | 12.15 |
| Performance Ratios | |||||
| ROA(%) | 9.88 | 15.36 | 13.59 | 10.19 | 9.94 |
| ROE(%) | 11.83 | 18.34 | 16.63 | 12.85 | 13.10 |
| ROCE(%) | 16.00 | 23.64 | 22.77 | 18.19 | 17.24 |
| Asset Turnover(x) | 1.00 | 1.08 | 1.16 | 1.11 | 1.15 |
| Sales/Fixed Asset(x) | 1.79 | 1.96 | 2.00 | 1.81 | 1.82 |
| Working Capital/Sales(x) | 2.28 | 2.08 | 2.50 | 2.63 | 3.03 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.56 | 0.51 | 0.50 | 0.55 | 0.55 |
| Receivable days | 52.05 | 50.64 | 45.49 | 44.13 | 42.19 |
| Inventory Days | 57.25 | 53.61 | 53.56 | 61.98 | 61.53 |
| Payable days | 115.96 | 108.56 | 103.64 | 111.52 | 98.28 |
| Valuation Parameters | |||||
| PER(x) | 25.47 | 22.08 | 29.28 | 25.95 | 32.65 |
| PCE(x) | 19.45 | 18.20 | 23.18 | 18.14 | 22.75 |
| Price/Book(x) | 2.87 | 3.75 | 4.53 | 3.11 | 3.95 |
| Yield(%) | 1.06 | 1.11 | 0.87 | 0.94 | 0.49 |
| EV/Net Sales(x) | 3.47 | 4.20 | 4.66 | 3.15 | 3.72 |
| EV/Core EBITDA(x) | 14.45 | 14.48 | 17.06 | 13.02 | 16.77 |
| EV/EBIT(x) | 18.52 | 16.81 | 20.73 | 17.27 | 22.52 |
| EV/CE(x) | 2.82 | 3.70 | 4.45 | 2.99 | 3.74 |
| M Cap / Sales | 3.51 | 4.23 | 4.68 | 3.19 | 3.78 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 2.23 | 6.88 | 13.28 | 4.55 | 13.59 |
| Core EBITDA Growth(%) | -15.33 | 13.53 | 27.90 | 13.83 | 6.98 |
| EBIT Growth(%) | -23.32 | 18.84 | 39.63 | 15.23 | 4.31 |
| PAT Growth(%) | -26.86 | 27.33 | 46.55 | 10.78 | 6.59 |
| EPS Growth(%) | -26.44 | 27.89 | 47.06 | 11.28 | 4.61 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.01 | - | 0.01 | 0.02 | 0.04 |
| Current Ratio(x) | 3.44 | 4.24 | 3.70 | 3.34 | 2.99 |
| Quick Ratio(x) | 2.50 | 3.21 | 2.70 | 2.31 | 1.91 |
| Interest Cover(x) | 97.04 | 111.00 | 64.44 | 37.87 | 33.85 |
| Total Debt/Mcap(x) | - | - | - | 0.01 | 0.01 |
Compare Financial Ratios of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹112,142.8 Cr | 0.7% | 1.9% | -4.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹429,145.0 Cr | -0.1% | -2.5% | 6.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹172,989.0 Cr | -0.2% | -2.8% | 1.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹149,322.0 Cr | 2.3% | 1.2% | 41.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,483.0 Cr | 0.1% | -2.4% | 2.3% | Stock Analytics | |
| MANKIND PHARMA | ₹97,382.6 Cr | 2.6% | -0.7% | -3.2% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 0.7% |
1.9% |
-4.7% |
| SENSEX | -1% |
-5.7% |
-9.7% |
You may also like the below Video Courses